IKT - inhibikase.com Trailing Twelve Months Revenue Growth

Inhibikase Therapeutics leverages the RAMP platform to develop exclusive therapies for neurodegenerative pathologies. However, geopolitical tensions and sanctions are hindering the international certification of new drugs. Year-over-year revenue dynamics over the last 12 months illustrate the impact of these factors, where -99.80 shows the value of this parameter. Simultaneously, the robotization of laboratory screening is accelerating the search for effective compounds to combat brain diseases.
Inhibikase Pharma (IKT) - metric breakdowns and financial figures

Investors view Inhibikase Therapeutics (IKT) as a high-risk asset whose value depends on FDA approval of drugs for Parkinson's disease. This trend in year-over-year sales over a 12-month period measures TTM revenue growth rates, neutralizing seasonal fluctuations and inflationary noise to assess the real operational dynamics of a biotech business protected by R&D patents.